Claims
- 1. A compound of the following formula:
- 2. A compound according to claim 1, wherein X=N.
- 3. A compound according to claim 1, wherein
R3 are the same or different and independently selected from the group consisting of:
H; C1-C4-straight chain alkyl; and C3-C4-branched chain alkyl; Y=H;
OR1; N(R1)2; N(R1)C(O)R3; N(R1)SO2R3; or N(R1)C(O)NHR3.
- 4. A compound according to claim 1, wherein
X=N; R3 are the same or different and independently selected from the group consisting of:
H; C1-C4-straight chain alkyl; and C3-C4-branched chain alkyl; Y=H;
OR1; N(R1)2; N(R1)C(O)R3; N(R1)SO2R3; or N(R1)C(O)NHR3.
- 5. A compound of the following formula:
- 6. A compound according to claim 5, wherein X=N.
- 7. A method of treating a mammal with a disorder mediated by elevated levels of cell proliferation compared to a healthy mammal comprising:
administering a therapeutically effective amount of the compound of claim 1 to the mammal under conditions effective to treat the disorder mediated by elevated levels of cell proliferation compared to a healthy mammal.
- 8. The method of claim 7, wherein the disorder mediated by elevated levels of cell proliferation compared to a healthy mammal is cancer, wherein the cancer is selected from the group consisting of breast cancer, colon cancer, central nervous system cancer, leukemia, melanoma, lung cancer, ovarian cancer, prostate cancer, and renal cancer.
- 9. The method of claim 7, wherein the disorder mediated by elevated levels of cell proliferation compared to a healthy mammal is restenosis.
- 10. The method of claim 7, wherein the mammal is human.
- 11. A pharmaceutical composition of matter comprising the compound of claim 1 and one or more pharmaceutical excipients.
- 12. A method of treating a mammal with a disorder mediated by elevated levels of cell proliferation compared to a healthy mammal comprising:
administering a therapeutically effective amount of the compound of claim 5 to the mammal under conditions effective to treat the disorder mediated by elevated levels of cell proliferation compared to a healthy mammal.
- 13. The method of claim 12, wherein the disorder mediated by elevated levels of cell proliferation compared to a healthy mammal is cancer, wherein the cancer is selected from the group consisting of breast cancer, colon cancer, central nervous system cancer, leukemia, melanoma, lung cancer, ovarian cancer, prostate cancer, and renal cancer.
- 14. The method of claim 12, wherein the disorder mediated by elevated levels of cell proliferation compared to a healthy mammal is restenosis.
- 15. The method of claim 12, wherein the mammal is human.
- 16. A pharmaceutical composition of matter comprising the compound of claim 5 and one or more pharmaceutical excipients.
- 17. A process for preparation of a purine derivative compound of the formula:
- 18. A process according to claim 17, wherein if Y is NHR1, said process further comprises:
reacting the purine derivative compound with R3C(O)Cl or R5C(O)Cl or R3SO2Cl or R3NCO or R6OC(O)Cl under conditions effective to form a final product having the same formula as the purine derivative compound except that Y is NR1C(O)R3 or Y is NR1C(O)R5 or NR1SO2R3 or NR1C(O)NHR3 or NR1C(O)OR6.
- 19. A process according to claim 17 further comprising:
reacting a second intermediate compound of the formula: 117with a second compound of the formula: 118wherein: V1=NH2;
OH; or SH; under conditions effective to form the first intermediate compound.
- 20. A process according to claim 19 further comprising:
reacting a third intermediate compound of the formula: 119with a compound of the formula R1-Z under conditions effective to form the second intermediate compound.
- 21. A process according to claim 17, wherein the purine derivative compound has the formula:
- 22. A process for preparation of a purine derivative compound of the formula:
- 23. A process according to claim 22 further comprising:
reacting a second intermediate compound of the formula: 123with a second compound of the formula: 124under conditions effective to form the first intermediate compound.
- 24. A process according to claim 23 further comprising:
reacting a third intermediate compound of the formula: 125with a compound of the formula: R2—B(OH)2, R2—Sn(n-Bu)3, or R2—Sn(Me)3, or mixtures thereof, under conditions effective to form the second intermediate compound.
- 25. A process according to claim 22 further comprising:
reacting a fourth intermediate compound of the formula: 126with a compound of the formula: R2—B(OH)2, R2—Sn(n-Bu)3, or R2—Sn(Me)3, or mixtures thereof, under conditions effective to form the first intermediate compound.
- 26. A process according to claim 25 further comprising:
reacting a fifth intermediate compound of the formula: 127with a compound of the formula: 128under conditions effective to form the fourth intermediate compound.
- 27. A process according to claim 22, wherein the purine derivative compound has the formula:
- 28. A process for preparation of a purine derivative compound of the formula:
- 29. A process according to claim 28, wherein if Y is NHR1, said process further comprises:
reacting the purine derivative compound with R3C(O)Cl or R5C(O)Cl or R3SO2Cl or R3NCO or R6OC(O)Cl under conditions effective to form a final product having the same formula as the purine derivative compound except that Y is NR1 C(O)R3 or NR1C(O)R5 or NR1SO2R3 or NR1C(O)NHR3 or NR1C(O)OR6.
- 30. A process according to claim 28 further comprising:
reacting a second intermediate compound of the formula: 133with a compound of the formula R1-Z where Z=Br or I, under conditions effective to form the first intermediate compound.
- 31. A process according to claim 30 further comprising:
reacting a third intermediate compound of the formula: 134with a compound of the formula 2,6-dichloropurine (Formula IV) under conditions effective to form the second intermediate compound.
- 32. A process according to claim 31 further comprising:
reacting a fourth intermediate compound of the formula: 135with a compound of the formula: R2—B(OH)2, R2—Sn(n-Bu)3, or R2—Sn(Me)3, or mixtures thereof, under conditions effective to form the third intermediate compound.
- 33. A process according to claim 28, wherein the purine derivative compound has the formula:
- 34. A process for preparation of a purine derivative compound of the formula:
- 35. A process according to claim 34 further comprising:
reacting a second intermediate compound having the same formula as the first intermediate compound except that Y is NH2, with R8CH2Z or R8CHO under conditions effective to form the first intermediate compound where Y=NHR1 or N(R1)2, wherein Z is Br or I, and R8 is C1-C5-straight chain alkyl, C2-C5-straight alkenyl chain, C3-C5-branched alkyl chain, C3-C5-branched alkenyl chain, C3-C7-cycloalkyl, CF3, or CH2CF3.
- 36. A process for preparation of a purine derivative compound of the formula:
Parent Case Info
[0001] This is a continuation-in-part of U.S. patent application Ser. No. 09/493,790, filed Jan. 28, 2000, which claims benefit from U.S. Provisional Patent Application Ser. No. 60/124,829, filed Mar. 17, 1999.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60124829 |
Mar 1999 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09493790 |
Jan 2000 |
US |
Child |
09950549 |
Sep 2001 |
US |